title: Novel dyskerin-mediated mechanism of p53 inactivation through defective mRNA translation.
abstract: In up to 60% of human cancers, p53 gene mutations are responsible for direct inactivation of the tumor suppressor function of p53. Alternative mechanisms of p53 inactivation described thus far mainly affect its posttranslational regulation. In X-linked dyskeratosis congenita, a multisystemic syndrome characterized by increased cancer susceptibility, mutations of the DKC1 gene encoding dyskerin cause a selective defect in the translation of a subgroup of internal ribosome entry site (IRES)-containing cellular mRNAs. In this study, we show that impairment of dyskerin function can cause p53 inactivation due to a defect in p53 mRNA translation. siRNA-mediated reduction of dyskerin levels caused a decrease of p53 mRNA translation, protein levels, and functional activity, both in human breast cancer cells and in primary mammary epithelial progenitor cells. These effects seemed to be independent of the known role of dyskerin in telomerase function, and they were associated with a specific impairment of translation initiation mediated by IRES elements present in p53 mRNA. In a series of human primary breast cancers retaining wild-type p53, we found that low levels of dyskerin expression were associated with reduced expression of p53-positive target genes. Our findings suggest that a dyskerin-mediated mechanism of p53 inactivation may occur in a subset of human tumors.
authors.affiliation: Dipartimento di Patologia Sperimentale, Università di Bologna, via San Giacomo 14, 40126 Bologna, Italy. lorenzo.montanaro@unibo.it
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Montanaro
authors.forename: Maria
authors.initials: M
authors.lastname: Calienni
authors.forename: Sara
authors.initials: S
authors.lastname: Bertoni
authors.forename: Laura
authors.initials: L
authors.lastname: Rocchi
authors.forename: Pasquale
authors.initials: P
authors.lastname: Sansone
authors.forename: Gianluca
authors.initials: G
authors.lastname: Storci
authors.forename: Donatella
authors.initials: D
authors.lastname: Santini
authors.forename: Claudio
authors.initials: C
authors.lastname: Ceccarelli
authors.forename: Mario
authors.initials: M
authors.lastname: Taffurelli
authors.forename: Domenica
authors.initials: D
authors.lastname: Carnicelli
authors.forename: Maurizio
authors.initials: M
authors.lastname: Brigotti
authors.forename: Massimiliano
authors.initials: M
authors.lastname: Bonafè
authors.forename: Davide
authors.initials: D
authors.lastname: Treré
authors.forename: Massimo
authors.initials: M
authors.lastname: Derenzini
mesh_terms: D001943:Breast Neoplasms / Q000235:genetics / Q000378:metabolism; D018797:Cell Cycle Proteins / Q000096:biosynthesis / Q000235:genetics*; D045744:Cell Line, Tumor; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D020868:Gene Silencing; D016158:Genes, p53; D006801:Humans; D009687:Nuclear Proteins / Q000096:biosynthesis / Q000172:deficiency / Q000235:genetics*; D014176:Protein Biosynthesis; D012333:RNA, Messenger / Q000235:genetics* / Q000378:metabolism; D019098:Telomerase / Q000378:metabolism; D016159:Tumor Suppressor Protein p53 / Q000096:biosynthesis / Q000235:genetics*
chemical_list: D018797:Cell Cycle Proteins; C112148:DKC1 protein, human; D009687:Nuclear Proteins; D012333:RNA, Messenger; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; D019098:Telomerase